88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling.
| Autor: | Pavlakis, N.1 (AUTHOR), Millward, M.2 (AUTHOR), Richardson, G.3 (AUTHOR), Andelkovic, V.4 (AUTHOR), Kichenadasse, G.5 (AUTHOR), Thomas, D.M.6 (AUTHOR), Mas Fernandez, A.7 (AUTHOR), Thakkar, D.7 (AUTHOR), Arbabzade, T.8 (AUTHOR), Goey, C.H.7 (AUTHOR), Seet, Q.7 (AUTHOR), Toy, W.7 (AUTHOR), Paszkiewicz, K.7 (AUTHOR), Ingram, P.J.7 (AUTHOR), Boyd-Kirkup, J.D.7 (AUTHOR), Kwek, K.Y.7 (AUTHOR) |
|---|---|
| Zdroj: | Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1501-S1501. 1p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|